Here are the 10-K annual reports from Tarsus Pharmaceuticals, Inc. (TARS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TARS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARS filings page.
Tarsus Pharmaceuticals files its annual report describing rapid growth of XDEMVY, its first approved eye-care drug for Demodex blepharitis, and a broader lotilaner-based pipeline. XDEMVY generated $451.4 million in net product sales in 2025, with about 400,000 bottles delivered and more than $646 million in sales since launch.
The company is advancing TP-04 into a Phase 2 trial for ocular rosacea, with topline data expected in the first half of 2027, and TP-05 into a Phase 2 Lyme disease prophylaxis trial planned to start in the second quarter of 2026. Tarsus highlights extensive licensing from Elanco, significant reliance on XDEMVY, single‑source manufacturing, and ongoing capital needs as key business risks.